FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Endo Wants Generic Epinephrine Restrictions

[ Price : $8.95]

Endo asks FDA not to receive or approve any applications for a generic form of Endos epinephrine products that do not refer to the...

Vaccine Skeptic Kennedy Confirmed as HHS Secretary

[ Price : $8.95]

The U.S. Senate votes 52-48 to confirm vaccine skeptic Robert F. Kennedy Jr. to serve as the next HHS secretary.

Study Sees New Trazodone Adverse Events

[ Price : $8.95]

Researchers in China say they found several new adverse event signals in their review of 20 years of FDA adverse event reports on ...

FDA Still Faster than EMA on Cancer Approvals

[ Price : $8.95]

A Friends of Cancer Research study update says FDA continues to review and approve novel cancer drugs faster than the European Med...

Sanofi/J&J Scrap E. Coli Vaccine Candidate

[ Price : $8.95]

Sanofi and Johnson & Johnson stop the development of their vaccine candidate for extraintestinal pathogenic E. coli because Phase ...

Court Rules for FDA in Vanda Label Case

[ Price : $8.95]

The DC District Court rules for FDA in a Vanda Pharmaceuticals lawsuit seeking an agency order to revoke the approval of a Teva AN...

DoJ Probing Inspire Marketing, Reimbursement

[ Price : $8.95]

The Department of Justice has requested information from Inspire Medical as part of a civil probe into its marketing, promotion, a...

FDA Clarifies Compounded GLP-1 Enforcement

[ Price : $8.95]

FDA clarifies its enforcement discretion timeframes for compounded tirzepatide.

Genentech Gets New Evrysdi Tablet Approval

[ Price : $8.95]

FDA approves a Genentech NDA for a new tablet formulation of Evrysdi (risdiplam) for treating people with spinal muscular atrophy.

Travere Therapeutics Plans Filspari sNDA

[ Price : $8.95]

Travere Therapeutics says it will submit an sNDA to FDA for a new indication for its Filspari to treat focal segmental glomerulosc...